111In-ABY-025

N/A

Report date: 2025/11/20 11:37:51
NME

Base Information

Drug Name111In-ABY-025
Drug Alias Name111In-[maleimide-DOTA-Cys61]-ZHER2-2891-Cys111In-ABY-025[111]In-ABY-025ABY-025-[111In]Indium-111-ABY-025
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionSingle-photon emission-computed tomography enhancersReceptor protein-tyrosine kinase erbB-2 antagonistsPositron-emission tomography enhancers
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAffibody Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiomedical Radiation SciencesAffibody Ab
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A